摘要
背景:最近的研究评估了循环肿瘤DNA(CTDNA)分析在检测NSCLC患者血浆表皮生长因子受体(EGFR)突变中的诊断准确性,总体上显示出与标准组织基因分型的高度一致性。然而,如果转移部位的位置可能影响识别EGFR突变的能力尚不清楚。 目的:本研究旨在评估转移位点的位置与CTNC分析对检测NSCLC患者EGFR突变的敏感性之间的关系。 方法:通过PubMed、Cochrane图书馆、美国临床肿瘤学协会和世界肺癌会议会议录,收集所有发表的研究,评估基于血浆的EGFRAMP测试的敏感性,通过转移部位定位(胸外(M1B)和胸内(M1A))分层肺癌的发病情况。根据转移位点的位置,计算cDNA分析灵敏度的混合比值(OR)和95%置信区间(95%顺式)。 结果:共有十项研究,其中1425例符合条件。汇总分析表明,CT1DNA的EGFR突变检测的敏感性在M1B与M1A疾病(OR:5.09;95% CIS:2.93–8.84)的患者中显著增高。EGFR激活(OR:4.30,95% CI:2.35-7.88)和抗性T790M突变(OR:11.89,95% CI:1.45-97.22),无论使用数字PCR(OR:5.85,95% CI:3.55-960)或非数字PCR技术(OR:2.96,95% CI:2.24~3.91),均观察到显著的关联。 结论:这些数据表明,转移位点的位置显著影响CTNC分析在检测NSCLC患者EGFR突变中的诊断准确性。
关键词: 表皮生长因子受体,ctDNA,液体活检,非小细胞(型)肺癌,转移部位,胸内,胸外。
Current Cancer Drug Targets
Title:Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis
Volume: 18 Issue: 7
关键词: 表皮生长因子受体,ctDNA,液体活检,非小细胞(型)肺癌,转移部位,胸内,胸外。
摘要: Background: Recent studies evaluated the diagnostic accuracy of circulating tumor DNA (ctDNA) analysis in the detection of epidermal growth factor receptor (EGFR) mutations from plasma of NSCLC patients, overall showing a high concordance as compared to standard tissue genotyping. However it is less clear if the location of metastatic site may influence the ability to identify EGFR mutations.
Objective: This pooled analysis aims to evaluate the association between the metastatic site location and the sensitivity of ctDNA analysis in detecting EGFR mutations in NSCLC patients.
Methods: Data from all published studies, evaluating the sensitivity of plasma-based EGFRmutation testing, stratified by metastatic site location (extrathoracic (M1b) vs intrathoracic (M1a)) were collected by searching in PubMed, Cochrane Library, American Society of Clinical Oncology, and World Conference of Lung Cancer, meeting proceedings. Pooled Odds ratio (OR) and 95% confidence intervals (95% CIs) were calculated for the ctDNA analysis sensitivity, according to metastatic site location.
Results: A total of ten studies, with 1425 patients, were eligible. Pooled analysis showed that the sensitivity of ctDNA-based EGFR-mutation testing is significantly higher in patients with M1b vs M1a disease (OR: 5.09; 95% CIs: 2.93 – 8.84). A significant association was observed for both EGFR-activating (OR: 4.30, 95% CI: 2.35-7.88) and resistant T790M mutations (OR: 11.89, 95% CI: 1.45-97.22), regardless of the use of digital-PCR (OR: 5.85, 95% CI: 3.56-9.60) or non-digital PCR technologies (OR: 2.96, 95% CI: 2.24-3.91).
Conclusions: These data suggest that the location of metastatic sites significantly influences the diagnostic accuracy of ctDNA analysis in detecting EGFR mutations in NSCLC patients.
Export Options
About this article
Cite this article as:
Metastatic Site Location Influences the Diagnostic Accuracy of ctDNA EGFR- Mutation Testing in NSCLC Patients: a Pooled Analysis, Current Cancer Drug Targets 2018; 18 (7) . https://dx.doi.org/10.2174/1568009618666180308125110
DOI https://dx.doi.org/10.2174/1568009618666180308125110 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
One-Step Synthesis of 1H-1,2,3-Triazol-1-Ylmethyl-2,3-Dihydronaphtho[1,2-b]furan- 4,5-Diones
Current Organic Synthesis Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine ROS-Responsive Nanomedicine: Towards Targeting the Breast Tumor Microenvironment
Current Medicinal Chemistry Ent-11α-Hydroxy-15-Oxo-Kaur-16-en-19-Oic-Acid Induces Apoptosis of Human Malignant Cancer Cells
Current Drug Targets Celecoxib in Cancer Therapy and Prevention – Review
Current Drug Targets ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities
Anti-Cancer Agents in Medicinal Chemistry Toxicity of Biodegradable Nanoscale Preparations
Current Drug Metabolism Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
Current Cancer Drug Targets Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and their Application in Drug Discovery
Current Medicinal Chemistry Lung Cancer Surgery in Patients with Chronic Obstructive Pulmonary Disease (COPD): Surgical Selection Challenges and Clinical Outcomes
Current Respiratory Medicine Reviews Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery
Current Pharmaceutical Design Targeted Therapies for Non-Small Cell Lung Cancer
Current Pharmaceutical Design Simultaneous determination of Curcumin (Cur) and Thymoquinone (THQ) in lipid based self-nanoemulsifying systems and its application to the commercial product using UHPLC-UV-Vis spectrophotometer
Current Pharmaceutical Analysis Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Molecular Kinetics and Targeting Within the Nucleus
Current Chemical Biology Tipping the Balance Between Life and Death: Targeting Histone Acetylation for Cancer Therapy
Drug Delivery Letters Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets